Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug

On Thursday, Amicus Therapeutics (NASDAQ:FOLD) announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. (NYSE:TEVA).

The agreement resolves the patent litigation brought by Amicus in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Galafold (migalastat) 123mg capsules before the expiration of the applicable patents.

Also Read: Teva Pays $450M To ...

Full story available on Benzinga.com